ABG
CAPR icon

Ally Bridge Group’s Capricor Therapeutics CAPR Stock Holding History

Ally Bridge Group’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-113,899
Closed -$3.46M – 27
2026
Q1 		$3.46M Buy
+113,899
New +$3.03M 2.8% 20

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ally Bridge Group's CAPR Position: Q2 2026 in Review

Ally Bridge Group sold out of Capricor Therapeutics (CAPR) in Q2 2026, closing a stake of 113,899 shares — an estimated $3.46M sold.

Ally Bridge Group first reported a position in CAPR in Q1 2026 and held it in 1 quarter. The position peaked at $3.46M in Q1 2026. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Ally Bridge Group reported no remaining Capricor Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Ally Bridge Group sold 113,899 Capricor Therapeutics shares in Q2 2026, an estimated $3.46M.
  • Ally Bridge Group first reported a position in Capricor Therapeutics in Q1 2026 and held it in 1 quarter.
  • Ally Bridge Group's Capricor Therapeutics position peaked at $3.46M in Q1 2026.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Ally Bridge Group's 13F filing for Q2 2026, filed 14 Aug 2026.